New legislation expands care for veterans exposed to burn pits, and Cleveland Clinic has developed a dedicated protocol to better treat deployers experiencing lung disease.
Investigating Novel Therapies for Scleroderma-Associated Interstitial Lung Disease
Cleveland Clinic is part of the largest scleroderma trial ever undertaken to evaluate the efficacy and safety of oral nintedanib treatment in systemic sclerosis associated interstitial lung disease.
Pirfenidone and Nintedanib: Novel Agents in the Treatment of Idiopathic Pulmonary Fibrosis
Two long-awaited novel agents, pirfenidone and nintedanib, now FDA- approved for the treatment of idiopathic pulmonary fibrosis, provide hope and improve understanding and treatment of devastating fibrotic lung diseases.
Transplant Drug Wins FDA Approval for Rare Lung Disease
Rapamycin — an FDA-approved drug to prevent organ rejection in kidney transplant patients — is providing hope for patients affected by a rare lung disease that almost exclusively affects women.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy